Andrew (“Andy”) Balo is Executive Vice President, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development at Dexcom.
Andy assumed the role of Executive Vice President, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development at Dexcom in May 2016. In this role, Andy is responsible for overseeing Dexcom’s clinical trials worldwide and developing global regulatory strategies related to these activities.
Since joining Dexcom in 2002, Mr. Balo has held several executive roles, including Executive Vice President, Clinical, Regulatory and Quality, Senior Vice President of Clinical and Regulatory Affairs and Vice President of Clinical and Regulatory Affairs.
Prior to joining Dexcom, Andy served as Vice President of Regulatory and Clinical Affairs for InnerCool Therapies and Endocardial Solutions. Andy also held several leadership positions at St. Jude Medical including Vice President, Regulatory, Clinical and Technical Services and Corporate Vice President, Quality, Regulatory and Clinical Affairs and was an officer of the company.
Andy received his Bachelor of Science degree in Microbiology and Chemistry from the University of Maryland and completed graduate studies at UCLA and Stanford University.